PULSAR with Fecal Transplant for Advanced Liver Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination treatment (PULSAR plus fecal microbiota transplant) for people with advanced liver cancer that stopped responding to initial therapy. It aims to see if this approach can help control the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that cannot be removed by surgery.
- Your cancer is at BCLC stage B or C.
- You have not received any previous systemic treatment for liver cancer.
- Your cancer initially responded to first-line treatment (targeted immunotherapy) but then started growing again.
- Your liver function is good, with a Child-Pugh score of 7 or less.
- You have at least one measurable tumor on a CT or MRI scan.
- You are in good physical condition (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help your liver cancer become sensitive again to treatment that has stopped working. It may help reverse drug resistance and improve outcomes for people with advanced liver cancer.
This trial tests whether giving a fecal transplant (a procedure that replaces the bacteria in your gut) can help people with advanced liver cancer whose current treatment has stopped working. It may help boost your immune system to fight the cancer.
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests combining a fecal transplant (healthy donor bacteria) with two drugs—QL1706 (an immunotherapy) and bevacizumab (a blood vessel blocker)—for people with advanced liver cancer that hasn't been treated before. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.